Hervé Affagard, MaaT Pharma CEO

FDA lifts near­ly two-year hold on MaaT Phar­ma's mi­cro­bio­me ther­a­py, opens door to PhI­II

Af­ter near­ly two years, the FDA has de­cid­ed a mi­cro­bio­me ther­a­py can now be test­ed in US pa­tients with acute graft-ver­sus-host dis­ease (aGVHD), lift­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.